Phaseline

Companies › Jiangsu vcare pharmaceutical technology

Jiangsu vcare pharmaceutical technology: clinical trials, targets and expected readouts

3 active drug programs in 9 registered trials: 5 Phase 3, 3 Phase 2, 1 Phase 1; Immunology, Cardiovascular, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VC004–Phase 3Locally Advanced Solid TumorDec 2026
Vicagrel
P2Y12 receptor antagonist
P2RY12Phase 3Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)Dec 2026
VC005 tablets
JAK inhibitor
–Phase 3Active Ankylosing Spondylitis; Moderate to Severe Atopic Dermatitis; Atopic Dermatitis; Non-segmental Vitiligo …Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06577519VicagrelPhase 3Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)CardiovascularDec 2026
NCT06658353VC004Phase 3Locally Advanced Solid TumorOncologyDec 2026
NCT07598383VC005 tabletsPhase 2Atopic DermatitisImmunologyFeb 2027
NCT07172360VC005 tabletsPhase 3Active Ankylosing SpondylitisImmunologyAug 2027
NCT06723080VC005 tabletsPhase 3Moderate to Severe Atopic DermatitisImmunologyAug 2027
NCT07172347VC005 tabletsPhase 2Non-segmental VitiligoImmunologyAug 2027
NCT07762443VC005 tabletsPhase 1Alopecia AreataImmunologyDec 2027
NCT07592585VC005 tabletsPhase 3Atopic DermatitisImmunologyMay 2028
NCT07749716VC005 tabletsPhase 2Alopecia AreataImmunologyDec 2028

Targets

P2RY12 (1)

Companies with the same targets

iVascular S.L.U. Viatris Innovation

Companies built like this

iVascular S.L.U. Viatris Innovation Industrial Farmacéutica Cantabria THPharm Swedish Orphan Biovitrum

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.